In a report published by Deputy et al in The New England Journal of Medicine, using data from Cosmos, a nationwide Epic electronic health record (EHR) database, investigators confirmed that the JYNNEOS vaccine was effective in preventing mpox and also found that a two-dose vaccine series conferred additional protection. In patients who received two doses, considered a full vaccination, the researchers found the estimated adjusted vaccine effectiveness was 66.0%; in those who received one dose, considered a partial vaccination, the estimated adjusted vaccine effectiveness was 35.8%. Patients with immunocompromising conditions were found to derive additional benefit from the vaccine: a two-dose series in this population resulted in a vaccine effectiveness rate of 76.3%, and a one-dose series was 40.8% effective. The authors also emphasized that these findings illustrate the importance of receiving a full vaccination series of JYNNEOS by completing both shots, as recent data published in Morbidity and Mortality Weekly Report showed that only about 57% of those who received their first dose and were eligible for a second actually completed the full series.
June 08, 2023